Estradiol/drospirenone explained

Estradiol/drospirenone (E2/DRSP), sold under the brand name Angeliq, is a combination of estradiol (E2), an estrogen, and drospirenone (DRSP), a progestin, antimineralocorticoid, and antiandrogen, which is used in menopausal hormone therapy, specifically the treatment of menopausal syndrome and osteoporosis, in postmenopausal women.^{[1] [2] [3]} It is taken by mouth and contains 0.5 to 1 mg E2 and 0.25 to 0.5 mg DRSP per tablet. The medication was approved in the United States in 2005. It is marketed widely throughout the world.^[4]

See also

• Estetrol/drospirenone
• Ethinylestradiol/drospirenone
• Ethinylestradiol/drospirenone/levomefolic acid
• Ethinylestradiol/drospirenone/prasterone
• List of combined sex-hormonal preparations § Estrogens and progestogens

External links

• Angeliq (estradiol/drospirenone) FDA Label
• Estradiol/drospirenone (Angeliq) - AdisInsight

Notes and References

1. Web site: ANGELIQ (drospirenone and estradiol) Prescribing Information . February 2012 . Bayer HealthCare Pharmaceuticals Inc. . U.S. Food and Drug Administration .
2. Web site: Estradiol/Drospirenone - Bayer HealthCare Pharmaceuticals . AdisInsight .
3. Rosano GM, Vitale C, Marazzi G, Volterrani M . Menopause and cardiovascular disease: the evidence . Climacteric . 10 . Suppl 1 . 19–24 . February 2007 . 17364594 . 10.1080/13697130601114917 . 7305124 .
4. Web site: Drospirenone and Estradiol: Uses, Side Effects & Warnings.